drugset / Trial / NCT04700319
CAR-T CD19/CD20 for Patients With Advanced CD19/CD20+ B Cell Line Recurrent or Refractory Hematological Malignancies
Phase 0
Unknown
30 enrolled
PersonGen BioTherapeutics (Suzhou) Co., Ltd.
Anhui Provincial Hospital · collab
NaSingle-groupOpen-labelPrevention
Summary
This is a clinical study of CD19 / CD20 CAR-T cell infusion in the treatment of relapsed or refractory hematological malignancies in CD19 / CD20 positive B cell lines. The aim of this study was to evaluate the efficacy and safety of autologous chimeric antigen receptor T cell infusion targeting CD19/CD20 in the treatment of relapsed or refractory CD19 / CD20 positive B cell line hematological malignancies.
Timeline
- Start
- 2019-04-19
- Primary completion
- 2021-05-01
- Completion
- 2021-06-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | CD19/CD20 CAR-T | Cell therapy | 200000 cells/kg | Intravenous |
| Subject | CD19/CD20 CAR-T | Cell therapy | 5e+06 cells/kg | Intravenous |
Indications
No indication recorded.